NextCell CSO Lindsay Davies Honoured with Multiple New Leadership Roles Within European Cell Therapy Community

NextCell CSO Lindsay Davies Honoured with Multiple New Leadership Roles Within European Cell Therapy Community

Davies' expertise critical to translating NextCell’s lead MSC product, ProTrans, through international late-stage clinical trials and into commercialisation

Huddinge, Sweden, May 8, 2025 – NextCell Pharma AB (“NextCell” or the “Company”), the Scandinavian leader in mesenchymal stromal cell (MSC) therapies, announces its Chief Scientific Officer (CSO), Dr Lindsay Davies, has been named to the Board of Advisors of Advanced Therapies Europe, and has begun her role as inaugural Chair of International Society for Cell & Gene Therapy (ISCT) European Industry Committee, launched last week to power new initiatives aimed at improving European policies affecting the advanced therapy industry.

These new honours follow her recent election as ISCT’s Vice President Elect for Europe, effective in June following two years as Secretary for Europe, as well as her appointment to the Swedish National Coordination Group for Advanced Therapies, and ATMP Sweden’s Board of Directors, where she has joined the cross-sectoral coordinating team as an industry representative.

“Lindsay's additional roles within the European advanced therapies community are well-earned recognitions of her long-standing leadership in the field. They reflect on the calibre of leaders we have at NextCell, where Lindsay has brought to bear translational experience ranging from her academic work at Karolinska Institute and Cardiff University to her commercial roles ever since," said NextCell CEO Mathias Svahn. “The demand for her talents also demonstrates the work we have ahead of us yet to build Sweden and Europe more broadly as the global leaders in MSCs and other cell therapies.”

"I am honoured to work with Advanced Therapies Europe, ISCT and ATMP Sweden to help build advanced therapies capabilities across Europe, where we are blessed with a broad range of competencies like world-leading universities and a top-tier talent pool. We will need to work across borders and sectors to secure our place as a stable and competitive environment to build advanced therapy businesses and infrastructure,” said Davies. “I look forward to continuing my work with partners across Europe to bring together academia, SMEs, start-ups and pharma to build a healthier future for patients in Europe and worldwide.”

As CSO, Davies has overseen the clinical development of ProTrans, NextCell's  allogeneic MSC therapy for type 1 diabetes, which is currently in Phase IIb testing in paediatric patients, ahead of a planned Phase III trial. Previous clinical data for ProTrans has been published in Diabetologia[1].

About NextCell Pharma AB

NextCell Pharma AB is a clinical-stage cell therapy company developing ProTrans, an advanced therapy medicinal product (ATMP) based on mesenchymal stromal cells (MSCs), currently in Phase II trials for the treatment of type 1 diabetes. The company’s primary goal is to obtain market approval through a planned Phase III trial in partnership with a future commercial collaborator. In addition to its clinical pipeline, NextCell owns Cellaviva AB – Scandinavia’s largest private stem cell bank – which is licensed by the Swedish Health and Social Care Inspectorate (IVO) to collect and store stem cells from umbilical cord blood and tissue for family use. NextCell also owns QVance, a provider of specialised quality control analytics for developers of advanced therapies. The company is listed on the Nasdaq First North Growth Market under the ticker symbol NXTCL.